We are building a pipeline to maximize the number of rSM medicines for patients.
Arrakis has a pipeline of RNA-targeted drug programs that show promise for addressing a range of diseases, including cancer, cardiovascular conditions, neurodegeneration and rare diseases. In addition to wholly-owned programs for rSM medicines in our internal pipeline, we are establishing collaborations with large biopharmaceutical partners to expand the productivity of our platform.
Collaborations to expand value:
As an example of our partnership model, learn about our strategic collaborations with Roche and Amgen.
We are expanding the universe of drug discovery and new treatments for patients
Arrakis is increasing the opportunities for small molecule medicines beyond the domain of well-studied protein targets for today's treatments. Specifically, this new universe has orders of magnitude more potential targets than those currently accessible to the field of medicine.
Our pipeline of rSM medicines
We have taken a matrixed approach to building our pipeline of RNA-targeted small molecule (rSM) medicines by pursuing different rSM modalities across deeply researched, valuable drug targets, including:
- known targets implicated in important disease biology that have historically proved "undruggable" with today's conventional medicines; and
- other genetically and pharmacologically validated targets in cancer, rare disease, and cardiovascular disease.
